Chlamydia pneumoniae is being recognized as a common cause of respiratory tract infections. Bronchoalveolar lavage specimens from human immunodeficiency virus-infected patients were examined by culture for this pathogen. Of 50 specimens examined, 5 (10%) were positive for C. pneumoniae. Four of these (80%) were also positive for other pathogens frequently implicated as causes of respiratory disease in this patient population. C. pneumoniae may frequently inhabit the respiratory tracts of human immunodeficiency virus-infected individuals.
Since the mid-1980s a body of literature has emerged describing outbreaks of respiratory tract infections caused by a species of chlamydia distinct from Chlamydia trachomatis and Chlamydia psittaci recently designated as Chlamydia pneumoniae (5) . Species-specific serologic studies have strongly suggested that this organism is the etiologic agent responsible for infection in populations as diverse as young, otherwise healthy military recruits and hospitalized patients with chronic diseases (4, 8) . Despite this accumulated experience, little epidemiologic information is available based upon the isolation of this organism by culture. This technique may be particularly important in patients for whom the antibody response is unreliable (e.g., patients with AIDS).
The response of immunocompromised patients to challenge with chlamydial species has not been fully explored. Information is scant on the mechanisms of resistance to chlamydial infections in humans. Humoral response, both immunoglobulin G (IgG) and IgM, has been well characterized for patients with C. trachomatis infections, although its role in the evolution of such processes is unclear (11) . The role of cell-mediated immunity in protecting against these intracellular pathogens, although clearly demonstrated in animal models, has not been readily shown in humans (14, 15) .
The potential for C. pneumoniae to act as a respiratory pathogen in human immunodeficiency virus (HIV)-infected patients deserves study. We obtained bronchoalveolar lavage specimens from randomly selected HIV-infected patients undergoing bronchoscopy for the diagnosis of unexplained pulmonary processes. These specimens were cultured for C. pneumoniae.
From A portion of each specimen was stored in chlamydia transport medium (sucrose-phosphate buffer with 10% fetal bovine serum and antibiotics) at -70°C. At a later date specimens were inoculated onto 24-well macrotiter plates containing HeLa 229 cell monolayers pretreated with DEAE-dextran. These were then centrifuged at 1,700 x g for 1 h. After 72 h of incubation at 37°C, the infected monolayers were scraped and the cells were sonicated and centrifuged at 500 x g. The supernatant was again inoculated onto new HeLa 229 cell monolayers. This procedure was repeated four times for each specimen. Cell layers separately prepared in 96-well microtiter plates at each passage were examined with genus-specific fluorescein-conjugated monoclonal antibody (Pathfinder Chlamydia Culture Confirmation System; Kallestad Diagnostics, Chaska, Minn.), specific anti-C. trachomatis monoclonal antibody (Microtrak Chlamydia trachomatis Culture Confirmation Test; Syva Co., Palo Alto, Ca.), and specific anti-C. pneumoniae antibody (Washington Research Foundation, Seattle).
Sera from these patients were not available for study.
Of the 50 specimens, 5 (10%) from HIV-infected patients were positive by culture for C. pneumoniae. Four specimens required at least two passages to yield discernible inclusions. The remaining positive specimen took three passages. Positive specimens had from 2 to 10 inclusions per well and stained brightly with both genus-specific and C. pneumoniae species-specific monoclonal antibody. None C-2 HIV infection, as defined by the classification system of the Centers for Disease Control. None of these patients received antimicrobial agents known to have significant activity against C. pneumoniae (2, 10). One patient received pentamidine, and three patients received antimycobacterial agents (i.e., isoniazid, rifampin, and pyrazinamide). The activities of these substances against C. pneumoniae have not been investigated. There were no identifiable routine physical, historical, or laboratory data which could distinguish patients with C. pneumoniae from the remainder of the patients studied.
Of the 14 patients without documented HIV infection, 1 patient was also positive by culture for C. pneumoniae.
We feel that finding C. pneumoniae in the bronchoalveolar lavage fluid of 10% of our HIV-infected patients was significant. Concomitant serologies would have been useful, although they are frequently difficult to interpret in HIVinfected patients. Most of our patients had other documented respiratory pathogens and seemed to respond clinically to therapy not specifically directed against C. pneumoniae. Thus, the role of this organism in the pathologic process remains unclear.
Evidence indicates that C. pneumoniae is a frequent cause of respiratory tract infections in humans. In previous epidemiologic studies done in various countries, the prevalence of antibody to C. pneumoniae ranged anywhere from 40 to 70% (3). These seropositive rates appeared to increase with increasing age (16) . Yet, how much of this reflects a history of symptomatic infection is not certain. Asymptomatic genital infection with C. trachomatis is well described. We have documented asymptomatic nasopharyngeal infection with C. pneumoniae with and without seroconversion (6) .
Patients with AIDS are at risk for infection with an ever-widening range of microorganisms. Yet, chlamydia have not been implicated as a common cause of infection in these patients. Although C. trachomatis has been documented to cause pneumonia rarely in certain immunocompromised adults, including those with leukemica (7) and bone marrow recipients (12) , only one well-documented case has been described in a patient with AIDS (9). Moncada et al. (13) Since chlamydiae are obligate intracellular parasites, isolation of the organism suggests infection and not simply colonization. The isolation of C. pneumoniae from the lungs of these HIV-infected patients may not imply an etiologic role for this organism in their pulmonary processes. Nor can we be certain about its possible role as an agent that modifies other infectious processes (e.g., superinfection). Additional information on the prevalence of infection with C. pneumoniae in the general population documented by culture along with concomitant serologic studies is needed before the true value of our findings can be appreciated.
